Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients COVID-Lamm Study on Behalf of Gelamm (Grupo de Estudio Latino- Americano de Mieloma Múltiple)

Background The SARS CoV-2 / COVID 19 pandemic has challenged the world's health systems, especially services that treat cancer. The first studies in China showed that cancer patients had a higher risk of becoming infected and dying. Other risk factors for mortality were age over 65 years, male...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez Cordero, Humberto, Peña, Camila, Fantl, Dorotea, Riva, Eloisa, Schutz, Natalia Paola, Abello, Virginia, Ruiz Arguelles, Guillermo, Ramirez Alvarado, Aline, Moreno Gómez, Lina, Von Glasenapp, Alana, Noboa, Andrea, Idrobo, Henry, Ospina Idarraga, Juan, Rojas, Christine, Pineda, Judith, Seehaus, Cristian, Remaggi, Guillermina, Sanchez, Sofia, Espinoza, Ramiro, Alvarado, Martha, De la Peña-Celaya, Jose Antonio, Perez, Juan Manuel, Arana-Luna, Luara L., Espitia, María Eugenia, Hernandez, Eleazar, David Salas, Lourdes, Herrera, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
651.Myeloma: Biology and Pathophysiology, excluding Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330368/
http://dx.doi.org/10.1182/blood-2020-142823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330368/
http://dx.doi.org/10.1182/blood-2020-142823

Ejemplares similares